Understand
What this competency means
Have a working understanding of moderate to severe AUD, relapse processes, craving, withdrawal, and common comorbidities. This knowledge is required to deliver the integrated treatment model safely and effectively.
This page is a Blossom synthesis of professional and study materials. It supports orientation and comparison; it does not replace local protocols, supervision, professional scope, or clinical judgment.
Apply
What it looks like in practice
Observable behaviours have not yet been reviewed for this competency. The page intentionally avoids inventing a proficiency ladder from sparse source material.
Verify
Across the manuals
A cross-source synthesis has not yet been reviewed for this competency. The representative evidence below shows the current provenance without implying agreement.
Representative evidence
Public provenance is a deterministic sample of the sources behind this synthesis. Pro readers receive the complete ledger when additional sources exist.
Guidelines and manuals
- Clinical Study Protocol BPL-003-203: Intranasal 5-MeO-DMT with Psychological Support in Alcohol Use Disorder5-MeO-DMT · 100
Beckley Psytech, 2024 (NCT05674929)
- BPL-003-203 Clinical Study Protocol: An Open-Label, Phase 2a Single Dose Study in Patients With Alcohol Use Disorder5-MeO-DMT · 90
Marsden et al., 2025
Explore 1 more linked source
The public sample shows how the synthesis is grounded. Blossom Pro adds the complete evidence ledger and framework depth.